AstraZeneca's 490 Million Talent Retention Plan: The Cost of Targeting N+3 Laid-off Employees

At the recent AstraZeneca China oncology business annual meeting, the company officially announced the "Dedication to Retain Talent Program," which involves a special investment in China, including cash and stock rewards totaling 490 million RMB.

According to the official announcement, AstraZeneca commits to providing a cash reward of 10% of the annual salary for employees below the managerial level, while those at the managerial level and above will receive a 20% equity incentive.

Shortly before this, AstraZeneca implemented layoffs affecting several product lines, with a compensation scheme of N+3 and a departure deadline of December 31. Despite this, some employees voluntarily applied for layoff positions.

Amid a series of challenges that have damaged the company's image, AstraZeneca chose this critical moment to distribute bonuses, aiming to stabilize employee morale and retain talent.

AstraZeneca, a global leading pharmaceutical company headquartered in London, UK, employs approximately 61,500 people worldwide, with its China headquarters located in Shanghai, making it one of the Fortune Global 500 companies.

According to AstraZeneca's Q3 2024 financial report, the company's revenue for the first three quarters reached $39.182 billion, a year-on-year increase of 19%; revenue for the third quarter stood at $13.565 billion, up 21%. In China, revenue for the first three quarters was $5.049 billion, a 15% year-on-year growth; the third quarter alone generated $1.671 billion, also reflecting a 15% increase. The Chinese market now accounts for about 13% of AstraZeneca's global revenue, underscoring its importance to the company.

While achieving impressive performance, AstraZeneca has also been noted for its excellent employee benefits, with industry insiders suggesting that its salary levels are among the highest in the field. The company offers flexible work arrangements, parental workdays, family days, special holidays, super annual leave, Christmas leave, Easter leave, family care leave, and long service leave, along with holiday bonuses and high-temperature allowances, demonstrating its commitment to employee welfare.

However, incidents such as insurance fraud allegations may affect the company’s operations in China, and some layoffs are related to this. Therefore, laid-off employees may encounter difficulties in their job searches.

On the evening of December 4, AstraZeneca announced the appointment of Iskra Reic as Global Executive Vice President and Head of International Business, responsible for regional strategic development, including China, and initiated a major personnel reshuffle in the China management team, including changes to the position of General Manager.

During the annual meeting, employees raised three core questions: What are the employment prospects for laid-off employees in the current situation? Will there be further layoffs? How will the company retain and incentivize talent? Although it could not confirm whether further layoffs would occur, AstraZeneca provided clear commitments regarding employee bonuses and benefits.

Given AstraZeneca's significant sales performance in China and its strong results in the first three quarters, the company must safeguard its position in the Chinese market during this exceptional period. The primary objective is to win over employees, stabilize morale, and retain talent. Employees are the foundation of a company; ensuring they feel accomplished and fulfilled is essential for retention and motivation, ultimately driving greater value for the company.